Marshall Wace’s Myovant Sciences Ltd. MYOV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-56,200
| Closed | -$1.52M | – | 3456 |
|
|
2022
Q4 | $1.52M | Buy |
56,200
+20,117
| +56% | +$529K | ﹤0.01% | 1885 |
|
|
2022
Q3 | $648K | Sell |
36,083
-597,222
| -94% | -$9.54M | ﹤0.01% | 2614 |
|
|
2022
Q2 | $7.87M | Buy |
+633,305
| New | +$6.99M | 0.02% | 1044 |
|
|
2022
Q1 | – | Sell |
-54,193
| Closed | -$844K | – | 4293 |
|
|
2021
Q4 | $844K | Buy |
+54,193
| New | +$1.03M | ﹤0.01% | 2551 |
|
|
2021
Q3 | – | Sell |
-25,814
| Closed | -$588K | – | 3579 |
|
|
2021
Q2 | $588K | Buy |
+25,814
| New | +$543K | ﹤0.01% | 2064 |
|
|
2021
Q1 | – | Sell |
-8,630
| Closed | -$238K | – | 2985 |
|
|
2020
Q4 | $238K | Buy |
+8,630
| New | +$168K | ﹤0.01% | 1709 |
|
|
2020
Q3 | – | Sell |
-165,934
| Closed | -$3.42M | – | 2024 |
|
|
2020
Q2 | $3.42M | Buy |
165,934
+127,175
| +328% | +$1.73M | 0.02% | 599 |
|
|
2020
Q1 | $293K | Buy |
+38,759
| New | +$435K | ﹤0.01% | 1102 |
|
|
2019
Q4 | – | Sell |
-70,217
| Closed | -$365K | – | 2182 |
|
|
2019
Q3 | $365K | Buy |
+70,217
| New | +$521K | ﹤0.01% | 1165 |
|
Other funds holding MYOV
Marshall Wace's MYOV Position: Q1 2023 in Review
Marshall Wace sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 56,200 shares — an estimated $1.52M sold.
Marshall Wace first reported a position in MYOV in Q3 2019 and held it in 9 quarters. The position peaked at $7.87M in Q2 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.
- Marshall Wace reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
- Marshall Wace sold 56,200 Myovant Sciences Ltd. shares in Q1 2023, an estimated $1.52M.
- Marshall Wace first reported a position in Myovant Sciences Ltd. in Q3 2019 and held it in 9 quarters.
- Marshall Wace's Myovant Sciences Ltd. position peaked at $7.87M in Q2 2022.
- 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.
Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.